Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fisher & Paykel Fiscal 2009 Operating Revenue Up 28%
Operating revenue Respiratory and acute care product group operating revenue increased by 34% to NZD244.5 million and OSA product group operating revenue increased by 23% to NZD202.6 million.
Operating revenue Respiratory and acute care product group operating revenue increased by 34% to NZD244.5 million and OSA product group operating revenue increased by 23% to NZD202.6 million.
Protopic ointment is licensed to teat severe eczema (atopic dermatitis), and approved for twice-weekly application by the patients. Protopic ointment’s approval was based on the data demonstrated by
The amendment contains testing results to establish self-life of the product. FDA has requested no additional clinical trial for Stelara Earlier in June 2008, FDA’s Dermatologic and Ophthalmic
The Phase 3 clinical trial (PHIRST-1) randomized, double-blind, 16-week placebo-controlled of Adcirca for PAH, patients taking Adcirca 40 mg (administered as two 20 mg tablets) once daily, achieved
In addition, Jiangsu Yanshen has received a new medicine certificate from the PRC State Food and Drug Administration (SFDA) for its freeze-dried human use rabies vaccine (vero cell).
FDA approval was based on safety and efficacy data from three pivotal trials with approximately 1,300 patients. The study demonstrated, patients taking Vimpat had their seizures reduced to
The company plans to file for marketing approvals worldwide under the trademarks ellaOne and ella, and continue to research pharmaceutical developments in the field of reproductive health that
KineMed’s stable isotope technology is a translational and personalized medicine platform to identify and characterize novel biomarkers in cerebrospinal fluid to facilitate development of new drugs for the
Acyclovir gel is used to treat skin infection due to varicella-zoster virus and herpes simplex virus. Shuanghuanglian suppositories helps relieve cold and flu symptoms such as fever, cough
Once approved, Bristol-Myers Squibb will begin Phase I trial in Sweden. Bristol-Myers Squibb will pay a consideration of $4 million to AMRI, as a result of the submission